News
Events
LumiraDx Reports Second Quarter 2022 Results
2022/08/18
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18 2022
2022/08/12
LumiraDx to Present on Impact of its Next-Generation Microfluidic Technology at American Association for Clinical Chemistry (AACC) Annual Conference in Chicago
2022/07/25
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
2022/07/21
LumiraDx Announces Proposed Public Offering of Common Shares
2022/07/19
London Loves Business: Groundbreaking Covid test gives lifeline to businesses as cases soar
2022/06/30
HealthTech World: The versatile diagnostic platform that passes the test
2022/06/14
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
2022/06/09
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
2022/06/08
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
2022/06/02
360Dx: LumiraDx Gets New, Expanded CE Marks for Point-of-Care Cardiovascular Disease Tests
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
2022/05/26
Medical Device Network: LumiraDx’s HbA1c test receives CE mark for diabetes screening
HealthTech World: LumiraDx receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
MD+DI: LumiraDx Scores CE Mark for Fast POC COVID-19 Test
2022/05/24
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
2022/05/20
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
2022/05/19
HealthTech World: Antimicrobial resistance: New guidance on using CRP tests in primary care to reduce antibiotic overprescribing
2022/05/18
LumiraDx Reports First Quarter 2022 Results
2022/05/11
Bill Gates Ted Talk: We Can Make COVID-19 the Last Pandemic | Bill Gates | TED
2022/04/29
Health Europa: Answering healthcare needs with point-of-care testing
2022/04/26
Forbes: Could The Innovation Stack Revolutionize Your Industry?
2022/04/15
Fast Company: Bill Gates wants to create a global pandemic first response team
2022/04/12
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
2022/03/10
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
2022/03/01
LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete
2022/02/21
Health Europa: LumiraDx: Fighting antimicrobial resistance with innovative POC testing
2022/01/26
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
2022/01/14
LumiraDx CRP Test Achieves CE Marking
2022/01/11
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B MicrofluidicAntigen Test
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
2021/12/23
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
2021/12/15
FDA Reissues LumiraDx Fast Lab Solutions’ EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
2021/12/01
LumiraDx Monitoring of New and Emerging Variants of Concern and Detection of the Omicron Variant
2021/11/29
LumiraDx Reports Third Quarter 2021 Financial Results
2021/11/10
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
2021/11/02
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
2021/10/20
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
2021/10/15
360Dx: Post-IPO, LumiraDx Pushes Adoption of POC Instrument, Eyes Test Menu Expansion
2021/10/07
360Dx: Point-of-Care Test Developer LumiraDx Goes Public on Nasdaq
2021/09/29
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
2021/09/28
Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19
2021/09/21
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
2021/08/20
PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate
2021/08/18
LumiraDx Receives FDA Emergency Use Authorization for its COVID-19 Antibody Test, Now Allowing COVID-19 Antigen and Antibody Testing on a Single Point of Care Platform
2021/08/05
LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test
2021/07/09
LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete
2021/07/02
LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta
2021/06/24
LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries
2021/06/17
Shionogi Announces Agreement of Joint Sales with LumiraDx Japan for Novel Coronavirus Antigen test agent and diagnostic instrument in Japan
2021/04/21
LumiraDx Receives Reissued FDA Emergency Use Authorization for Its High Sensitivity, Rapid COVID-19 Molecular Lab Test
2021/04/13
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp
2021/04/07
Bloomberg: Test Maker LumiraDx to Go Public in $5 Billion SPAC Deal
2021/04/06
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
2021/01/21
SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients
2021/01/13
LumiraDx Receives Authorization by Switzerland´s Federal Office of Public Health
2020/12/21
Global Partnership to Introduce a Connected, Point of Care Diagnostic Platform for COVID-19 Antigen Testing in Africa
2020/11/10
LumiraDx COVID-19 Antigen Test Achieves CE Mark
2020/08/31
LumiraDx Receives FDA Emergency Use Authorization for Point of Care COVID-19 Antigen Test
2020/08/20
LumiraDx at NHS Innovation Expo wins Silver at the World Exhibition Stand Awards 2020
2020/06/24
Drive through Warfarin Clinic supported by LumiraDx
2020/05/19
LumiraDx and Chembio announce COVID-19 Strategic Partnership
2020/03/12
LumiraDx Launches first-of-its-kind smart Diagnostic platform
2019/08/29